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Brucellosis is one of the most common zoonoses worldwide. Subunit vaccines are
promising for the prevention of human brucellosis. In our previous protective antigen
screening studies, we identified a new protective antigen, BMEI0357, which belongs to
the Lrp/asnC protein family, a conserved transcriptional regulator in bacteria that is absent
in eukaryotes. In the present study, the Brucella genome annotation was screened and a
total of six proteins were identified as members of the Lrp/AsnC family. Lrp/AsnC proteins
have two domains that are conserved among the family members. However, sequence
similarities between these proteins ranged from 9 to 50%, indicating high sequence
heterogeneity. To test whether proteins of this family have similar characteristics, all
six proteins were cloned and expressed in Escherichia coli. The recombinant proteins
were purified and their protective efficacy was evaluated in BALB/c mice challenged with
Brucella melitensis 16M. The results show that all six Lrp/AsnC proteins could induce
a protective immune response against Brucella melitensis 16M. Antibodies against the
Lrp/AsnC proteins were detected in the immunized mice. However, levels of antibodies
against these proteins were relatively variable in human brucellosis sera. Taken together,
our results show that these six proteins of the Lrp/AsnC family in Brucella could induce
protective immune responses in mice.
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INTRODUCTION
Brucellosis is one of the most common zoonoses worldwide, and is caused by bacteria of the
Brucella genus. As a zoonosis, brucellosis causes great economic and health losses. The increasing
incidence in recent years has shown some characteristics that are different from those observed
about 10 years ago (Pappas et al., 2006). New trends in brucellosis make it more challenging: the
spread from rural areas to cities, rapid expansion from one place to another, travel-related spread,
and long existence in many wild animals (Seleem et al., 2010; Chen et al., 2013).
Brucellosis is a vaccine-preventable disease. Until now, the live attenuated vaccine has
been the most efficient vaccine for this infection (Schurig et al., 2002). With extensive
vaccination programs, the incidence of brucellosis has decreased to relatively low levels.
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Indeed, some countries have even announced the complete
elimination of brucellosis. However, rigorous inspection
programs have shown a resurgence in incidence in many
developing countries in the recent years. Live attenuated
vaccines have several limitations, including residual virulence,
side effects, and reversion to virulent strains. These limitations
have restricted their extensive application, particularly for
human vaccination.
Subunit vaccines have several advantages over live vaccines
that make them appealing for development of new vaccines.
A protective antigen is a fundamental requirement of subunit
vaccines; therefore, much effort has been made to find ideal
antigens for subunit vaccine development (Pasquevich et al.,
2009; Perkins et al., 2010). In our previous antigen screening
study, we successfully identified a new protective antigen
belonging to the Lrp/AsnC protein family that is encoded by the
BMEI0357 gene in Brucella melitensis (Fu et al., 2012). Proteins
of the Lrp/AsnC family are conserved among bacteria but do
not exist in eukaryotic organisms (Brinkman et al., 2003). These
proteins regulate expression of many other genes within various
functional categories (Cho et al., 2008). That is, proteins of
this family are involved in regulation of many biological and
pathological processes. These characteristics make them good
candidates for drug and vaccine development for these pathogens
(Peeters and Charlier, 2010).
The Lrp/AsnC protein family may have several members
within a particular bacterial genus. Whether Brucella also
encodes several members of the Lrp/AsnC family remains
unknown. We addressed this question and then asked whether
these proteins could also serve as protective antigens for use in a
brucellosis vaccine. In the present study, we screened the genome
annotation of Brucella for proteins of Lrp/AsnC family. These
Lrp/AsnC family genes were cloned and expressed in Escherichia
coli, and the protective roles of these recombinant proteins were
evaluated by virulent strain challenge in vivo.
MATERIALS AND METHODS
Mice and Ethics Statement
Female 6-week-old BALB/c mice were obtained from the
Animal Center of Military Medical Sciences. All animals
were handled in strict accordance with Experimental Animal
Regulation Ordinances defined by the Chinese National Science
and Technology Commission. The animal work was approved
by the Beijing Institute of Disease Control and Prevention
Animal Ethics Committee (BIDCP003-2014). Animals were
provided with humane care and healthful conditions during
their stay in the facility. All individuals who used animals
had received instruction in experimental methods and in the
care, maintenance, and handling of mice, and were under the
committee’s supervision.
Cloning, Expression, and Purification of
His-Tagged Recombinant Proteins
Genome annotation of B. melitensis 16M was screened to
find genes encoding proteins of Lrp/AsnC family (DelVecchio
et al., 2002). The Lrp/AsnC proteins were cloned and expressed
essentially as previously described (Fu et al., 2012). Briefly,
the selected open reading frames (ORFs) were amplified
by PCR using genomic DNA of B. melitensis 16M with
specific primers tailed with restriction sites (Table S1). The
amplified DNA fragments were digested with appropriate
enzymes and subcloned into similarly digested pET28a. The
recombinant proteins were expressed in E. coli BL21 as
N-terminally His-tagged fusion proteins. The expression of
the recombinant proteins was verified by SDS-PAGE. The
recombinant fusion proteins were then purified by affinity
chromatography on Ni2+-conjugated chelating sepharose. The
purity of the purified proteins was assessed by SDS-PAGE
and the concentrations were quantified with a Nanodrop-1000
(NanoDrop, USA).
Immunization and Protection Experiments
Female 6-week-old BALB/c mice were immunized via the
intraperitoneal (i.p.) route with purified recombinant proteins
as described previously (Fu et al., 2012). Briefly, mice were
immunized with 200µL of recombinant proteins (30µg) or
PBS (negative control) mixed with complete Freund’s adjuvant
(Sigma-Aldrich, St. Louis, MO, USA) on day 0 and with
incomplete Freund’s adjuvant (Sigma-Aldrich) on day 15. Mice
were vaccinated with live attenuated vaccine strain S19 as
a positive control. At 30 days after the last immunization,
mice were challenged i.p. with 1 × 105 CFU of B. melitensis
virulent strain 16M. Mice were sacrificed by cervical dislocation
14 days post challenge and spleens were removed aseptically
and homogenized with PBS containing 0.1% Triton X-100.
The homogenates were serially diluted and plated on TSA
plates, and the CFU were counted after 5 days of incubation
37◦C.
Humoral Immune Response
Sera were collected from the immunized mice at 45 days
after the first immunization and immediately prior to
the challenges. Antibodies were detected in the sera with
ELISA by using the recombinant proteins as coating antigens
with standard procedures. ELISA for detecting the antibody
responses was performed essentially as previously described
(Li et al., 2012). Written informed consent was given to
brucellosis patient. Institutional ethics committee approved
the use of human sera. Human sera were collected from
confirmed brucellosis patients and stored at −20◦C before
use.
Statistical Analysis
The protective efficacy was expressed as reduction of the
mean log10 CFU ± SD. The differences between groups were
analyzed by ANOVA followed by Tukey’s honest significant
difference posttest by comparing the groups to one another.
For ANOVA, p-values of 0.05 were considered statistically
significant.
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RESULTS
Members of the Lrp/AsnC Family in B.
melitensis are Conserved in Structure but
Diverse in Sequence
Of the protective antigens identified in our previous screening
study, the antigen encoded by BMEI0357 was demonstrated
to induce high levels of cell-mediated immunity and provide
protection against virulent strain challenge. Sequence analysis
showed that BMEI0357 belongs to the Lrp/AsnC protein family.
Careful inspection of the genome annotation showed that there
were another five proteins that belong to the Lrp/AsnC family
of transcription regulators. As shown in Table 1, five of the
six proteins consist of two domains, an N-terminal AsnC-
type helix–turn–helix (HTH) domain and a C-terminal AsnC
transcriptional regulatory domain. The amino acid length of
the five proteins ranged from 146 to 168. One exception
to these proteins is BMEI1845, which is 78 amino acids in
length and encodes only one AsnC transcriptional regulatory
domain. Sequence comparisons between these proteins showed
that there were only 9–50% identities among these proteins,
implying that sequences of the AsnC protein family are relatively
heterogeneous (Figure 1).
Expression and Purification of Lrp/AsnC
Proteins in Soluble Form
To test whether these Lrp/AsnC proteins are also protective
antigens for Brucella, these proteins were cloned and expressed
as recombinant proteins. Full-length ORFs were amplified with
PCR primers that specifically amplify the coding sequences. The
PCR products were digested and then subcloned into expression
plasmid pET28a to generate the recombinant expression
plasmids. DNA sequencing results showed that all these genes
were correctly subcloned. Expression of recombinant proteins
was induced with IPTG and tested by SDS-PAGE, the results of
which indicate that all these proteins were successfully expressed
(Figures 2A,B). Sediments and supernatants of the bacterial
lysates were analyzed by SDS-PAGE to test the expression forms.
TABLE 1 | Domain details of the six proteins of the Lrp/AsnC familya.
AsnC protein Domain name Accession Description Interval (aa)
BMEI0357(168aa) HTH_ARSR cd00090 Arsenical resistance operon repressor 18–91
HTH_ASNC smart00344 Helix_turn_helix ASNC type; 17–125
HTH_24 pfam13412 Winged helix-turn-helix DNA-binding; 17–64
AsnC_trans_reg pfam01037 AsnC family; 83–156
Lrp COG1522 Transcriptional regulators 13–165
PRK11169 PRK11169 Leucine-responsive transcriptional regulator 16–168
BMEI1098 (159aa) HTH_ARSR cd00090 Arsenical resistance operon repressor 2–50
HTH_ASNC smart00344 Helix_turn_helix ASNC type 1–110
AsnC_trans_reg pfam01037 AsnC family; 67–140
HTH_AsnC-type pfam13404 AsnC-type helix-turn-helix domain; 1–42
Lrp COG1522 Transcriptional regulators [Transcription] 1–149
PRK11169 PRK11169 Leucine-responsive transcriptional regulator 1–149
BMEI1845 (78aa) AsnC_trans_reg pfam01037 AsnC family; 6–75
Lrp COG1522 Transcriptional regulators [Transcription] 4–75
BMEII0346 (146) HTH_ASNC smart00344 Helix_turn_helix ASNC type 4–107
HTH_24 pfam13412 Winged helix-turn-helix DNA-binding; 4–51
Lrp COG1522 Transcriptional regulators [Transcription] 1–143
PRK11169 PRK11169 Leucine-responsive transcriptional regulator 2–137
BMEII0375(155aa) HTH_ARSR cd00090 Arsenical Resistance Operon Repressor 5–53
HTH_ASNC smart00344 Helix_turn_helix ASNC type 4–113
AsnC_trans_reg pfam01037 AsnC family; 70–144
HTH_24 pfam13412 Winged helix-turn-helix DNA-binding; 4–51
Lrp COG1522 Transcriptional regulators [Transcription] 1–151
PRK11169 PRK11169 Leucine-responsive transcriptional regulator 3–133
BMEII0395(160aa) HTH_ASNC smart00344 Helix_turn_helix ASNC type 16–120
HTH_AsnC-type pfam13404 AsnC-type helix-turn-helix domain; 16–57
Lrp COG1522 Transcriptional regulators [Transcription] 11–158
PRK11169 PRK11169 Leucine-responsive transcriptional regulator 14–156
aAmino acid sequences of the six Lrp/AsnC proteins were blasted against database with PHI-BLAST. Aligned domain information was extracted and compared.
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FIGURE 1 | Sequence similarity between the Lrp/AsnC proteins in Brucella melitensis. Amino acid sequences of the Lrp/AsnC proteins were extracted and
aligned with MegAlign. (A) Sequence alignment of the six Lrp/AsnC proteins. (B) Percent identity of the amino acid sequence of the six Lrp/AsnC proteins.
Proteins were expressed in both inclusion bodies and soluble
forms. For better activity, recombinant proteins were purified
with Ni-NTA from soluble lysates. All six recombinant
proteins were successfully obtained with good purity
(Figure 2C).
Immunization with Lrp/AsnC Proteins
Induces Protection against 16M Challenge
in Mice
To evaluate the possible roles of the Lrp/AsnC proteins in
induction of protective immune responses, BALB/c mice were
immunized with the purified proteins and then challenged with
B. melitensis virulent strain 16M. For comparison, live attenuated
vaccine strain S19 and PBS were used as positive and negative
controls, respectively. Groups of six mice were immunized with
recombinant proteins, S19, or PBS, and then at 45 days after
the first immunization, mice were challenged with 16M. Spleens
were isolated from the mice at 14 days post challenge, and
bacteria in the spleens were enumerated. As shown in Table 2,
compared with the PBS group, the bacterial number in spleens
from the S19 group decreased significantly, indicating that
immunization of S19 had reduced the bacterial number in the
spleen and the protective efficacy of S19 was 1.77 logs. Very
interestingly, all six recombinant Lrp/AsnC proteins showed
significantly decreased bacterial numbers in spleens compared
with the negative control. Of the six proteins, BMEI1098 (1.46
logs) and BMEI1845 (1.46 logs) showed the highest protection
levels, followed by BMEII0375 (1.5 logs), BMEII0395 (1.4 logs),
BMEII0346 (1.4 logs), and BMEI0357 (1.2 logs). Compared with
the other proteins, BMEI0357 appeared to offer the lowest level
of protection. To record the reduction in inflammation caused
by the virulent strains, isolated spleens were photographed
and compared. Compared with non-immunized mice, spleen
inflammation and organ index was reduced in the protein-
immunized mice (Figure 3). Taken together, these data indicate
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FIGURE 2 | Expression and purification of recombinant Lrp/AsnC
proteins. Open reading frames of Lrp/AsnC proteins were cloned in
expression plasmid pET28a, transformed into E. coli, and induced with IPTG.
The bacterial lysates were analyzed by SDS-PAGE. (A) SDS-PAGE of
BMEI1098, BMEI1845, and BMEII0346. Lanes 1, 5, 9: un-induced control;
lanes 2, 6, 10: induced lysates; lanes 3, 7, 11: lysate sediments; lanes 4, 8,
12: lysate supernatants. (B) SDS-PAGE of BMEII0375, BMEII0395,
BMEI0357. Lanes 1, 4, 7: un-induced control; Lanes 2, 5, 8: lysate sediments;
Lames 3, 6, 9: lysate supernatants. (C) SDS-PAGE of purified proteins. 1–6:
BMEI0357, BMEII0395, BMEII0375, BMEII0346, BMEI1845, and BMEI1098.
that immunization with the Lrp/AsnC proteins could induce
protection against virulent Brucella.
Antibodies against Lrp/AsnC Proteins
Detected in Immunized Mice Sera and
Human Patient Sera
Although antibody responses play less important roles in
protection against Brucella infection, immunization using live
attenuated vaccine or antigens also induced antibody responses.
TABLE 2 | Protection efficacies of the Lrp/AsnC family proteins.
Vaccine protein Adjuvant Log10 cfu/spleen Unit of protection P-value
a
BMEI0357 CFA/IFA 4.83 ± 0.25 1.2 0.0019
BMEI1098 CFA/IFA 4.57 ± 0.25 1.46 0.0009
BMEI1845 CFA/IFA 4.57 ± 0.25 1.46 0.0002
BMEII0346 CFA/IFA 4.63 ± 0.53 1.4 0.0113
BMEII0375 CFA/IFA 4.53 ± 0.58 1.5 0.0119
BMEII0395 CFA/IFA 4.63 ± 0.50 1.4 0.0094
S19 IFA 4.26 ± 0.21 1.77 0.0003
PBS CFA/IFA 6.03 ± 0.15 – –
aLog10 cfu/spleen of immunized group is compared with that of PBS control with t-test,
p < 0.05 is statistically significant.
To test whether Lrp/AsnC family proteins also induced antibody
responses, sera were collected from immunized mice at 45 days
after the first immunization. Antibodies were detected with
ELISA by using the immunization proteins as coating antigens.
As shown in Figure 4A, all these proteins induced high levels
of antibodies at 45 days post immunization. Of these proteins,
BMEI1098 induced the highest level of antibodies, followed by
BMEI1845 and BMEI0395. Antibody level was not significantly
correlated with protection unit for these proteins (p = 0.5166).
The successful detection of antibodies against Lrp/AsnC
family proteins in sera from immunized mice implied that these
antibodies might also exist in sera of human brucellosis patients.
To test this hypothesis, sera were collected from brucellosis
patients and detected by ELISA using the purified recombinant
proteins as coating antigens. As shown in Figure 4B, antibodies
to one or more of these proteins were detected in 8 of the 10
patient sera. However, antibody titers differed among the sera
and proteins. Antibodies to BMEI0395 were detected in 7 of the
10 sera. BMEI0346 reacted with six of the sera samples. For sera
samples, S02 reacted with all six proteins, followed by S01, S05,
and S03 sera samples. Sera samples S06 and S07 did not react with
any of the proteins. These data indicate that although antibodies
to Lrp/AsnC proteins exist in patient sera, the distribution differs
in terms of both proteins and patient sera.
DISCUSSION
Bacteria have the capability to adapt to various environments,
which is important for their survival and virulence (Celli,
2006). To realize these adaptations, bacteria have evolved many
sensing and response systems that regulate gene expression. The
Lrp/AsnC family of transcriptional regulators was firstly found to
be involved in amino acidmetabolism regulation. This regulation
system is widely distributed among different bacteria but is absent
in eukaryotes (Brinkman et al., 2003; Peeters and Charlier, 2010).
Therefore, proteins of this regulatory family are good candidates
for vaccines and drug targets for pathogenic bacteria. In our
protective antigen screening, we identified a new protective
antigen, BMEI0357. Sequence analysis showed that BMEI0357
belongs to the Lrp/AsnC protein family. As demonstrated in
other bacterial genera, the Lrp/AsnC family typically has several
members. This prompted us to ask whether there are other
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FIGURE 3 | Reduction of spleen inflammation in the immunized mice after challenge. Immunized mice were challenged with 16M and 14 days post challenge
the spleens were isolated and photographed. (A) Immunization reduced the spleen inflammation and organ index (B) of the challenged mice.
members of the Lrp/AsnC family and whether these proteins also
have protective roles.
Genome sequence analysis revealed a wide phyletic
distribution of full-length Lrp-like transcriptional regulators
among prokaryotes. In 53% of the analyzed genomes, one or
more Lrp-like transcriptional regulators could be identified.
About 45% of the bacterial and 94% of the archaeal genomes
contain at least one Lrp homolog. In some bacterial genomes,
over a dozen of Lrp paralogs are present, whereas in others only
a few, or none are observed. Some bacterial endosymbionts
without Lrp paralogs completely depend on their host for the
supply of amino acids and other key metabolites (Brinkman
et al., 2003). The genome annotation of the B. melitensis 16M
was screened for members of the Lrp/AsnC family, resulting
in the identification of six genes. Proteins of the Lrp/AsnC
family usually have two domains: an AsnC transcriptional
regulatory domain and an Lrp domain. Except for BMEI1845, all
these putative Lrp/AsnC proteins contained these two domains
(Table 1).
To analyze the potential protective roles of the Lrp/AsnC
proteins, ORFs of the six genes were subcloned into the
pET28a expression plasmid and expressed in E. coli. All six
proteins were expressed in both soluble and inclusion-body form.
Proteins were purified in their soluble forms from supernatants
and used to immunize BALB/c mice. Effective protection
was confirmed by challenging the mice with virulent 16M
strain. Compared with non-immunized control, bacteria isolated
from the spleens of the immunized mice were significantly
reduced in number, indicating that immunization with the
recombinant proteins had induced protective immune responses.
As expected, immunization with BMEI0357 induced protective
immune responses. The protective efficacies of the recombinant
proteins were slightly lower than that of S19, a live attenuated
strain of Brucella. This result indicates that immunization
with recombinant Lrp/AsnC proteins could provide significant
protection. Because the immunizing protein antigens are purified
from E. coli, there might be some residual LPS contaminated
in the antigens that also induce immune responses. Even with
this possibility, the protections are still mainly mediated by the
immunization protein antigens, for the procedures are the same
as what we used in previous study, where only small part of the
proteins are found to be protective antigens (Fu et al., 2012).
Proteins of the Lrp/AsnC family have unique structures that
are closely related to their functions. LrpA from Pyrococcus
furiosus is the first protein of the Lrp/AsnC family, the structure
of which has been solved (Sedelnikova et al., 2001). LrpA forms
an octamer consisting of four dimers. The N-terminal part
of the protein is an HTH domain, a fold generally involved
in DNA binding (Cui et al., 1995). This N-terminal HTH
has been predicted for several Lrp-like proteins. The HTH of
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FIGURE 4 | Antibody responses induced by Lrp/AsnC family proteins. Purified recombinant proteins were used as coating antigen to detect antibodies in
immunized mice sera (A) and brucellosis patient sera (B).
LrpA is connected through a hinge to its C-terminal domain
(Sedelnikova et al., 2001). In E. coli Lrp, the C-terminal domain
has been shown to be involved in the response to leucine and
activation of transcription. The C-terminus of Lrp-like proteins
has a βαββαβ-fold or αβ-sandwich, in which the two α-helices
are located at one side of the four-stranded antiparallel β-
sheet. LrpA forms a homodimer mainly through the interactions
between the β-strands of this C-terminal domain, and an octamer
through further interactions between the second α-helix and
fourth β-strand of the βαββαβ motif (de los Rios and Perona,
2007). In the present study, we strikingly found that all the
Lrp/AsnC proteins could induce protective immune responses.
Because the sequence identities of these proteins were relative
low, their protective roles might be primarily determined by
their structural characteristics. Previous studies have shown that
multimeric proteins are good inducers of immunity. Proteins
of the Lrp/AsnC family can form multimers, therefore, it is
possible that protective immunity might be induced by the
multimeric forms of these proteins. However, this does not
exclude other possibilities. Because protection against Brucella is
mainly mediated by cell-mediated immunity, it is possible that
these proteins generate similar T-cell epitopes (He et al., 2010). It
will be interesting to investigate into protection mechanisms of
Lrp/AsnC proteins.
To characterize the immunogenicity of the recombinant
proteins, antibodies were detected in sera samples from the
immunized mice. The results show that all the proteins induced
antibodies after immunization. In our previous study, BMEI0357
was found to induce cell-mediated immune responses, as
demonstrated by the observation that re-stimulation of S19-
immunized spleens induced significant titers of IFN-gamma.
Since cell-mediated immunity is the main response that
provides protection, these proteins are possibly inducers of
cell-mediated immunity. In our future work, we will further
characterize the cell-mediated immunity of these proteins.
Lrp/AsnC proteins form multimers, a unique characteristic of
these proteins that makes them good inducers of immune
responses. The six proteins differ from each other in terms
of amino acid sequence, but all these proteins could induce
protective immune responses. At present, it remains to
be defined whether this characteristic resulted from the
formation of multimers. Therefore, it is of great interest to
the test roles of multimers in the protective efficacy of the
vaccine.
To test whether humoral responses were induced in human
patients, the recombinant proteins were used as coating antigens
and their antibodies were detected in the sera obtained from
brucellosis patients. Of the 10 sera found to be positive by a
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plate angulation test, eight were positive for antibodies to the
Lrp/AsnC proteins. The two negative sera samples might have
resulted from the detection method and antigens. The plate
angulation test uses whole-cell antigens, and the reactivity is
mediated mainly by LPS from bacteria. Antibody titers for these
proteins differed. Taken together, these data suggest that the
Lrp/AsnC proteins induced different antibody responses during
human infection. The reasons for this low reactivity might
include: the Lrp/AsnC proteins were poor inducers of humoral
responses, they induced very low levels of antibodies, or they
cross-reacted with other proteins and were removed from the
analysis.
In summary, the Lrp/AsnC proteins in Brucella were highly
heterogeneous in terms of amino acid sequence, but conserved
in terms of structural domains. Immunization with recombinant
proteins of this family induced protective immune responses
against virulent strain challenge in mice. Taken together, our
results show that proteins of the Lrp/AsnC family are protective
antigens for Brucella in mice, and this is the first report to show
the protective roles of Lrp/AsnC proteins.
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